TP53 and acute myeloid leukemia: A significant difference was found in the median OS between the 3 groups (p ≤ 0.0001) in the respect of mutant/wild TP53 status (Figure 4) (918 days for wild-type cases—AML-MR: 341, MDS-IB: 260, MDS-LB: 1101, while 224 days for mutant patients—AML-MR: 199, MDS-IB: 58.5, MDS-LB: 626 days, as well).